Novavax (NVAX) shares soared 10.9% in the last trading session to close at $10.82. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.6% gain over the past four weeks.The surge in stock price came as investors turned their attention toward the potential demand for vaccines targeting the H5N1 virus, also known as bird flu. On Monday, the U.S. CDC reported the first human death in the country from bird flu. The company is currently ...

Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S. GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global compan ...

It has been about a month since the last earnings report for Novavax (NVAX) . Shares have added about 13.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Novavax due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q3 Earnings & Sales Beat EstimatesNovavax incurred a t ...

Novavax (NVAX) announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.The study will compare the immunogenicity and safety of the CIC vaccine with separate administrations of Novavax’s currently authorized COVID-19 vaccine and a licensed seasonal influenza vaccine. Management will also assess the immunogenicity and safety of its standalone influenza vaccine.Both experimental vaccin ...

Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021. However, these healthcare specialists are actively trying to return to their outperforming ways. If they succeed, they will produce outsize returns for investors who purc ...

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 millionGAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ ...

Novavax, Inc. (NASDAQ:NVAX) Jefferies London Healthcare Results Conference November 20, 2024 6:00 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Ruxandra Draghia - Head of R&D Conference Call Participants Roger Song - Jefferies Roger Song Alright. Okay. So, sorry for the couple minutes late, but it's my pleasure. My name is Roger Song. I'm one of the senior analysts who covers mid-cap biotech in the US, and then my pleasure to introduce our next compan ...

GAITHERSBURG, Md., Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date"). These award ...

Novavax (NVAX) incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per share.Revenues in the quarter amounted to $85 million, which beat the Zacks Consensus Estimate of $57 million. However, the top line declined 55% on a year-over-year basis.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.More on NVAX’s EarningsNovavax recorded $38.2 million in produ ...

GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference. Conference Details: Fireside Chat Date: Wednesday, November 20, 2024 Time: 11:00 – 11:25 a.m. Greenwich Mean Time Location: London, United Kingdom Moderator: Roger Song, MD, CFA, Equity Analyst Novavax participants: John C. Jacobs, Presid ...